Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
Top Cited Papers
- 23 May 2008
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 371 (9625), 1665-1674
- https://doi.org/10.1016/s0140-6736(08)60725-4
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)The Lancet, 2008
- Development, cytokine profile and function of human interleukin 17–producing helper T cellsNature Immunology, 2007
- Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasisHuman Genetics, 2007
- A Large-Scale Genetic Association Study Confirms IL12B and Leads to the Identification of IL23R as Psoriasis-Risk GenesAmerican Journal of Human Genetics, 2007
- Prevalence of cardiovascular risk factors in patients with psoriasisJournal of the American Academy of Dermatology, 2006
- What have we learned in dermatology from the biologic therapies?Journal of the American Academy of Dermatology, 2006
- Validation of immunoassays used to assess immunogenicity to therapeutic monoclonal antibodiesJournal of Pharmaceutical and Biomedical Analysis, 2005
- PsoriasisThe New England Journal of Medicine, 2005
- A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasisJournal of the American Academy of Dermatology, 2004
- Severe Mycobacterial and Salmonella Infections in Interleukin-12 Receptor-Deficient PatientsScience, 1998